SEC Filing Summary: Stellar Biotechnologies, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Stellar Biotechnologies, Inc. on November 13, 2014. The report serves to announce the company's financial results for the fourth quarter and the full fiscal year ended August 31, 2014. The registrant is incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not detail specific material changes or comparative data versus prior periods within the text provided. Investors must refer to the attached press release (Exhibit 99.1) for a comparison of the fourth quarter and fiscal year results against prior comparable periods.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in the attached press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual financial figures for the quarter and fiscal year ended August 31, 2014.
- Verify the company name discrepancy: The request metadata lists "Edesa Biotech, Inc.," but the filing is for "Stellar Biotechnologies, Inc."
- Confirm the fiscal year-end date of August 31, 2014, when analyzing historical performance.
- Check for any subsequent filings that may provide updated liquidity or debt status.